As of May 27
| -3.00 / -4.25%|
The 13 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 107.00, with a high estimate of 180.00 and a low estimate of 63.00. The median estimate represents a +58.35% increase from the last price of 67.57.
The current consensus among 15 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.